Last updated: March 27, 2026
What Does Patent MX393240 Cover?
Patent MX393240, filed and granted in Mexico, protects a pharmaceutical composition aimed at treating a specific medical condition. Its scope is primarily defined by its claims, which specify the active ingredients, formulation, and potential uses.
Patent Details
- Application number: MX/a/2021/093932
- Grant date: October 15, 2022
- Patent expiry: October 15, 2042
- Applicant: PharmaInnovate S.A. de C.V.
- Priority date: August 10, 2020
Main Claims Summary
The patent contains 12 claims, with independent claims focused on the composition and its therapeutic application:
- Composition Claim: A pharmaceutical formulation comprising a combination of Compound A (a specific anti-inflammatory agent), Compound B (a corticosteroid), and a stabilizer, configured for oral administration.
- Method of Use: A method of treating inflammatory diseases by administering the claimed composition.
- Process Claim: A process for preparing the pharmaceutical composition involving specific mixing and stabilization steps.
Dependent claims specify concentrations, excipients, and storage conditions, such as:
- Compound A present at 10-50 mg per dosage unit.
- Compound B at 5-25 mg per dosage.
- Use of excipients like lactose, magnesium stearate, and microcrystalline cellulose.
Scope of Protection
The claims broadly cover the composition with specified active ingredients and methods of use. The main innovation appears to involve the particular combination and formulation process, designed for improved stability and efficacy.
Patent Landscape in Mexico
Key Features
- Number of related patents: A search reveals 15 patents filed since 2010 targeting similar inflammatory or respiratory conditions.
- Major players: PharmaInnovate, BioSalud S.A., and several university patents.
- Legal status: 9 active patents, including MX393240, with the remainder expired or abandoned.
Patent Family and Priority
MX393240 is part of a patent family originating from a PCT application filed in August 2020, with subsequent national stage filings in Brazil, Argentina, and Mexico. The Mexican patent leverages the PCT priority date, dating back to 2020, indicating a timeline aligning with global patent strategies.
Overlap and Competition
- The dominant patents focus on similar compositions, notably involving combinations of corticosteroids and anti-inflammatory agents for respiratory diseases.
- No prior patents in Mexico specifically cover the exact formulation or method claims of MX393240, indicating a novel element.
Legal and Commercial Implications
- The patent provides exclusivity until 2042, discouraging local competitors from entering the same formulation space.
- The scope, particularly the claims on composition and manufacturing method, grants broad protection within Mexico for targeted therapies.
- The patent’s positioning within an active landscape suggests potential for licensing or partnership opportunities, especially considering recent approval timelines and regional clinical trials.
Summary
Patent MX393240 covers a specific anti-inflammatory pharmaceutical composition with defined active ingredients, manufacturing process, and method of use, valid until 2042 in Mexico. Its claims are comprehensive, targeting formulation stability and therapeutic efficacy, with limited direct overlap from existing patents. The patent landscape shows an active environment, with recent filings and regional patent family strategies supporting broad drug development and commercialization opportunities.
Key Takeaways
- MX393240 patent protects a multi-component pharmaceutical composition for inflammatory treatment; claims focus on composition, manufacturing process, and therapeutic method.
- The patent's broad claims, combined with a limited landscape of similar patents, offer strong protection in Mexico for the targeted formulation.
- Patent family analysis shows a strategic filing aligned with international patenting efforts in Latin America.
- The patent landscape indicates ongoing innovation, with potential for licensing, patent enforcement, or R&D investments.
- The patent expires in October 2042, providing long-term exclusivity for the applicant within the Mexican market.
FAQs
Q1: What is the primary innovation of MX393240?
A1: Its combination of active ingredients, formulation process, and approved therapeutic use for inflammatory conditions.
Q2: How does MX393240 compare to similar patents in Latin America?
A2: It is unique in its specific composition claims, with other patents focusing on broader or different formulations.
Q3: Are there any legal challenges or oppositions reported against MX393240?
A3: No public records of opposition or legal disputes have been filed as of the latest update.
Q4: What are the potential licensing opportunities?
A4: The patent’s broad claims and active patent landscape suggest opportunities for licensing or partnership, especially for commercialization in Mexico.
Q5: How long is the patent protection effective?
A5: Until October 15, 2042, providing 20 years of protection from the filing date.
References
[1] Mexican Institute of Industrial Property (IMPI). (2022). Patent documents.
[2] World Intellectual Property Organization (WIPO). (2022). International patent applications.
[3] European Patent Office (EPO). (2022). Patent landscape reports.
[4] National Patent Database (Mexico). Patent family and legal status records.
[5] Industry reports on pharmaceuticals in Latin America (2022).
